Biotech Values

[rkrw]

MNTA. Everyone is entitled to an opinion. And I think dew isn't the only one who would have preferred someone other than NVS. But there's different ways of looking at the deal. I still think it's tough to criticize a deal when the partner tosses in two of their own drugs.

So I liked the deal. Validation of the lovenox deal by coming back for seconds. Pulled in stakes in 2 new products that they called late stage doubles the near to mid term shots on goal. Very aggressive partner was a must given the potential for patent challenges, politics and fda indecision. Mystery generic is a $1B+ drug, so the 2 leads are $1B++. Sandoz takes over lovenox EU anda filings which shouldn't take too long. Can't wait to see the Sandoz 2. So I think it was a great deal and better than I would have expected.